Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Nat Commun ; 12(1): 1799, 2021 03 19.
Article in English | MEDLINE | ID: mdl-33741965

ABSTRACT

Bacterial ribosome rescue pathways that remove ribosomes stalled on mRNAs during translation have been proposed as novel antibiotic targets because they are essential in bacteria and are not conserved in humans. We previously reported the discovery of a family of acylaminooxadiazoles that selectively inhibit trans-translation, the main ribosome rescue pathway in bacteria. Here, we report optimization of the pharmacokinetic and antibiotic properties of the acylaminooxadiazoles, producing MBX-4132, which clears multiple-drug resistant Neisseria gonorrhoeae infection in mice after a single oral dose. Single particle cryogenic-EM studies of non-stop ribosomes show that acylaminooxadiazoles bind to a unique site near the peptidyl-transfer center and significantly alter the conformation of ribosomal protein bL27, suggesting a novel mechanism for specific inhibition of trans-translation by these molecules. These results show that trans-translation is a viable therapeutic target and reveal a new conformation within the bacterial ribosome that may be critical for ribosome rescue pathways.


Subject(s)
Neisseria gonorrhoeae/drug effects , Protein Biosynthesis/drug effects , Protein Synthesis Inhibitors/pharmacology , Ribosomes/drug effects , Animals , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Binding Sites/genetics , Caco-2 Cells , Female , Gonorrhea/microbiology , Gonorrhea/prevention & control , Humans , Mice , Neisseria gonorrhoeae/genetics , Protein Biosynthesis/genetics , Protein Synthesis Inhibitors/chemistry , RNA, Bacterial/genetics , RNA, Bacterial/metabolism , Ribosomal Proteins/genetics , Ribosomal Proteins/metabolism , Ribosomes/genetics , Ribosomes/metabolism
2.
mBio ; 11(1)2020 02 25.
Article in English | MEDLINE | ID: mdl-32098812

ABSTRACT

Mutations in the Plasmodium falciparum Kelch 13 (PfK13) protein are associated with artemisinin resistance. PfK13 is essential for asexual erythrocytic development, but its function is not known. We tagged the PfK13 protein with green fluorescent protein in P. falciparum to study its expression and localization in asexual and sexual stages. We used a new antibody against PfK13 to show that the PfK13 protein is expressed ubiquitously in both asexual erythrocytic stages and gametocytes and is localized in punctate structures, partially overlapping an endoplasmic reticulum marker. We introduced into the 3D7 strain four PfK13 mutations (F446I, N458Y, C469Y, and F495L) identified in parasites from the China-Myanmar border area and characterized the in vitro artemisinin response phenotypes of the mutants. We found that all the parasites with the introduced PfK13 mutations showed higher survival rates in the ring-stage survival assay (RSA) than the wild-type (WT) control, but only parasites with N458Y displayed a significantly higher RSA value (26.3%) than the WT control. After these PfK13 mutations were reverted back to the WT in field parasite isolates, all revertant parasites except those with the C469Y mutation showed significantly lower RSA values than their respective parental isolates. Although the 3D7 parasites with introduced F446I, the predominant PfK13 mutation in northern Myanmar, did not show significantly higher RSA values than the WT, they had prolonged ring-stage development and showed very little fitness cost in in vitro culture competition assays. In comparison, parasites with the N458Y mutations also had a prolonged ring stage and showed upregulated resistance pathways in response to artemisinin, but this mutation produced a significant fitness cost, potentially leading to their lower prevalence in the Greater Mekong subregion.IMPORTANCE Artemisinin resistance has emerged in Southeast Asia, endangering the substantial progress in malaria elimination worldwide. It is associated with mutations in the PfK13 protein, but how PfK13 mediates artemisinin resistance is not completely understood. Here we used a new antibody against PfK13 to show that the PfK13 protein is expressed in all stages of the asexual intraerythrocytic cycle as well as in gametocytes and is partially localized in the endoplasmic reticulum. By introducing four PfK13 mutations into the 3D7 strain and reverting these mutations in field parasite isolates, we determined the impacts of these mutations identified in the parasite populations from northern Myanmar on the ring stage using the in vitro ring survival assay. The introduction of the N458Y mutation into the 3D7 background significantly increased the survival rates of the ring-stage parasites but at the cost of the reduced fitness of the parasites. Introduction of the F446I mutation, the most prevalent PfK13 mutation in northern Myanmar, did not result in a significant increase in ring-stage survival after exposure to dihydroartemisinin (DHA), but these parasites showed extended ring-stage development. Further, parasites with the F446I mutation showed only a marginal loss of fitness, partially explaining its high frequency in northern Myanmar. Conversely, reverting all these mutations, except for the C469Y mutation, back to their respective wild types reduced the ring-stage survival of these isolates in response to in vitro DHA treatment.


Subject(s)
Antimalarials/pharmacology , Artemisinins/pharmacology , Drug Resistance/genetics , Plasmodium falciparum/drug effects , Plasmodium falciparum/genetics , Protozoan Proteins/genetics , Asia, Southeastern , Drug Resistance/drug effects , Humans , Malaria, Falciparum/parasitology , Mutation , Organisms, Genetically Modified
3.
J Infect Dis ; 218(3): 434-442, 2018 07 02.
Article in English | MEDLINE | ID: mdl-29659945

ABSTRACT

Background: Falcipain-2a ([FP2a] PF3D7_1115700) is a Plasmodium falciparum cysteine protease and hemoglobinase. Functional FP2a is required for potent activity of artemisinin, and in vitro selection for artemisinin resistance selected for an FP2a nonsense mutation. Methods: To investigate associations between FP2a polymorphisms and artemisinin resistance and to characterize the diversity of the enzyme in parasites from the China-Myanmar border, we sequenced the full-length FP2a gene in 140 P falciparum isolates collected during 2004-2011. Results: The isolates were grouped into 8 different haplotype groups. Haplotype group I appeared in samples obtained after 2008, coinciding with implementation of artemisinin-based combination therapy in this region. In functional studies, compared with wild-type parasites, the FP2a haplotypes demonstrated increased ring survival, and all haplotype groups exhibited significantly reduced FP2a activity, with group I showing the slowest protease kinetics and reduced parasite fitness. Conclusions: These results suggest that altered hemoglobin digestion due to FP2a mutations may contribute to artemisinin resistance.


Subject(s)
Antimalarials/pharmacology , Artemisinins/pharmacology , Cysteine Endopeptidases/genetics , Drug Resistance , Genetic Variation , Malaria, Falciparum/parasitology , Plasmodium falciparum/drug effects , China , DNA, Protozoan/chemistry , DNA, Protozoan/genetics , Haplotypes , Humans , Myanmar , Plasmodium falciparum/genetics , Plasmodium falciparum/isolation & purification , Sequence Analysis, DNA
4.
Int J Parasitol Drugs Drug Resist ; 7(2): 131-137, 2017 08.
Article in English | MEDLINE | ID: mdl-28319724

ABSTRACT

The 8-aminoquinoline tafenoquine (TFQ), a primaquine derivative, is currently in late-stage clinical development for the radical cure of P. vivax. Here drug interactions between TFQ and chloroquine and six artemisinin-combination therapy (ACT) partner drugs in P. falciparum asexual stages and gametocytes were investigated. TFQ was mostly synergistic with the ACT-partner drugs in asexual parasites regardless of genetic backgrounds. However, at fixed ratios of 1:3, 1:1 and 3:1, TFQ only interacted synergistically with naphthoquine, pyronaridine and piperaquine in gametocytes. This study indicated that TFQ and ACT-partner drugs will likely have increased potency against asexual stages of the malaria parasites, whereas some drugs may interfere with each other against the P. falciparum gametocytes.


Subject(s)
Aminoquinolines/pharmacology , Antimalarials/pharmacokinetics , Artemisinins/pharmacology , Drug Synergism , Plasmodium falciparum/drug effects
5.
Sci Rep ; 6: 33891, 2016 10 03.
Article in English | MEDLINE | ID: mdl-27694982

ABSTRACT

Drug resistance has emerged as one of the greatest challenges facing malaria control. The recent emergence of resistance to artemisinin (ART) and its partner drugs in ART-based combination therapies (ACT) is threatening the efficacy of this front-line regimen for treating Plasmodium falciparum parasites. Thus, an understanding of the molecular mechanisms that underlie the resistance to ART and the partner drugs has become a high priority for resistance containment and malaria management. Using genome-wide association studies, we investigated the associations of genome-wide single nucleotide polymorphisms with in vitro sensitivities to 10 commonly used antimalarial drugs in 94 P. falciparum isolates from the China-Myanmar border area, a region with the longest history of ART usage. We identified several loci associated with various drugs, including those containing pfcrt and pfdhfr. Of particular interest is a locus on chromosome 10 containing the autophagy-related protein 18 (ATG18) associated with decreased sensitivities to dihydroartemisinin, artemether and piperaquine - an ACT partner drug in this area. ATG18 is a phosphatidylinositol-3-phosphate binding protein essential for autophagy and recently identified as a potential ART target. Further investigations on the ATG18 and genes at the chromosome 10 locus may provide an important lead for a connection between ART resistance and autophagy.


Subject(s)
Antimalarials/pharmacology , Drug Resistance/genetics , Genetic Loci , Plasmodium falciparum/genetics , Polymorphism, Single Nucleotide , Protozoan Proteins/genetics , China , Genome-Wide Association Study , Myanmar
6.
Antimicrob Agents Chemother ; 59(11): 6952-9, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26324266

ABSTRACT

Artemisinin resistance in Plasmodium falciparum parasites in Southeast Asia is a major concern for malaria control. Its emergence at the China-Myanmar border, where there have been more than 3 decades of artemisinin use, has yet to be investigated. Here, we comprehensively evaluated the potential emergence of artemisinin resistance and antimalarial drug resistance status in P. falciparum using data and parasites from three previous efficacy studies in this region. These efficacy studies of dihydroartemisinin-piperaquine combination and artesunate monotherapy of uncomplicated falciparum malaria in 248 P. falciparum patients showed an overall 28-day adequate clinical and parasitological response of >95% and day 3 parasite-positive rates of 6.3 to 23.1%. Comparison of the 57 K13 sequences (24 and 33 from day 3 parasite-positive and -negative cases, respectively) identified nine point mutations in 38 (66.7%) samples, of which F446I (49.1%) and an N-terminal NN insertion (86.0%) were predominant. K13 propeller mutations collectively, the F446I mutation alone, and the NN insertion all were significantly associated with day 3 parasite positivity. Increased ring-stage survival determined using the ring-stage survival assay (RSA) was highly associated with the K13 mutant genotype. Day 3 parasite-positive isolates had ∼10 times higher ring survival rates than day 3 parasite-negative isolates. Divergent K13 mutations suggested independent evolution of artemisinin resistance. Taken together, this study confirmed multidrug resistance and emergence of artemisinin resistance in P. falciparum at the China-Myanmar border. RSA and K13 mutations are useful phenotypic and molecular markers for monitoring artemisinin resistance.


Subject(s)
Artemisinins/pharmacology , Plasmodium falciparum/drug effects , Artemisinins/therapeutic use , China , Drug Resistance, Multiple/genetics , Genotype , Malaria, Falciparum/drug therapy , Mutation , Myanmar , Plasmodium falciparum/pathogenicity , Quinolines/pharmacology , Quinolines/therapeutic use
7.
Antimicrob Agents Chemother ; 59(12): 7650-6, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26416869

ABSTRACT

Currently, the World Health Organization recommends addition of a 0.25-mg base/kg single dose of primaquine (PQ) to artemisinin combination therapies (ACTs) for Plasmodium falciparum malaria as a gametocytocidal agent for reducing transmission. Here, we investigated the potential interactions of PQ with the long-lasting components of the ACT drugs for eliminating the asexual blood stages and gametocytes of in vitro-cultured P. falciparum strains. Using the SYBR green I assay for asexual parasites and a flow cytometry-based assay for gametocytes, we determined the interactions of PQ with the schizonticides chloroquine, mefloquine, piperaquine, lumefantrine, and naphthoquine. With the sums of fractional inhibitory concentrations and isobolograms, we were able to determine mostly synergistic interactions for the various PQ and schizonticide combinations on the blood stages of P. falciparum laboratory strains. The synergism in inhibiting asexual stages and gametocytes was highly evident with PQ-naphthoquine, whereas synergism was moderate for the PQ-piperaquine, PQ-chloroquine, and PQ-mefloquine combinations. We have detected potentially antagonistic interactions between PQ and lumefantrine under certain drug combination ratios, suggesting that precautions might be needed when PQ is added as the gametocytocide to the artemether-lumefantrine ACT (Coartem).


Subject(s)
Antimalarials/pharmacology , Plasmodium falciparum/drug effects , Primaquine/pharmacology , Sporozoites/drug effects , Trophozoites/drug effects , Benzothiazoles , Chloroquine/pharmacology , Diamines , Drug Combinations , Drug Interactions , Erythrocytes/drug effects , Erythrocytes/parasitology , Ethanolamines/pharmacology , Flow Cytometry , Fluorenes/pharmacology , Humans , Lumefantrine , Mefloquine/pharmacology , Organic Chemicals , Parasitic Sensitivity Tests , Plasmodium falciparum/growth & development , Quinolines/pharmacology , Sporozoites/growth & development , Trophozoites/growth & development
8.
Malar J ; 14: 168, 2015 Apr 18.
Article in English | MEDLINE | ID: mdl-25927592

ABSTRACT

BACKGROUND: The recent emergence and spread of artemisinin resistance in the Greater Mekong Subregion poses a great threat to malaria control and elimination. A K13-propeller gene (K13), PF3D7_1343700, has been associated lately with artemisinin resistance both in vitro and in vivo. This study aimed to investigate the K13 polymorphisms in Plasmodium falciparum parasites from the China-Myanmar border area where artemisinin use has the longest history. METHODS: A total of 180 archived P. falciparum isolates containing 191 parasite clones, mainly collected in 2007-2012 from the China-Myanmar area, were used to obtain the full-length K13 gene sequences. RESULTS: Seventeen point mutations were identified in 46.1% (88/191) parasite clones, of which seven were new. The F446I mutation predominated in 27.2% of the parasite clones. The C580Y mutation that is correlated with artemisinin resistance was detected at a low frequency of 1.6%. Collectively, 43.1% of the parasite clones contained point mutations in the kelch domain of the K13 gene. Moreover, there was a trend of increase in the frequency of parasites carrying kelch domain mutations through the years of sample collection. In addition, a microsatellite variation in the N-terminus of the K13 protein was found to have reached a high frequency (69.1%). CONCLUSIONS: This study documented the presence of mutations in the K13 gene in parasite populations from the China-Myanmar border. Mutations present in the kelch domain have become prevalent (>40%). A predominant mutation F446I and a prevalent microsatellite variation in the N-terminus were identified, but their importance in artemisinin resistance remains to be elucidated.


Subject(s)
Plasmodium falciparum/genetics , Polymorphism, Genetic , Protozoan Proteins/genetics , Antimalarials/pharmacology , Artemisinins/pharmacology , China , Mutation , Myanmar , Plasmodium falciparum/drug effects , Protozoan Proteins/metabolism
9.
PLoS Pathog ; 10(6): e1004080, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24967715

ABSTRACT

Alternatively activated macrophages (AAM) that accumulate during chronic T helper 2 inflammatory conditions may arise through proliferation of resident macrophages or recruitment of monocyte-derived cells. Liver granulomas that form around eggs of the helminth parasite Schistosoma mansoni require AAM to limit tissue damage. Here, we characterized monocyte and macrophage dynamics in the livers of infected CX3CR1(GFP/+) mice. CX3CR1-GFP⁺ monocytes and macrophages accumulated around eggs and in granulomas during infection and upregulated PD-L2 expression, indicating differentiation into AAM. Intravital imaging of CX3CR1-GFP⁺ Ly6C(low) monocytes revealed alterations in patrolling behavior including arrest around eggs that were not encased in granulomas. Differential labeling of CX3CR1-GFP⁺ cells in the blood and the tissue showed CD4⁺ T cell dependent accumulation of PD-L2⁺ CX3CR1-GFP⁺ AAM in the tissues as granulomas form. By adoptive transfer of Ly6C(high) and Ly6C(low) monocytes into infected mice, we found that AAM originate primarily from transferred Ly6C(high) monocytes, but that these cells may transition through a Ly6C(low) state and adopt patrolling behavior in the vasculature. Thus, during chronic helminth infection AAM can arise from recruited Ly6C(high) monocytes via help from CD4⁺ T cells.


Subject(s)
Antigens, Ly/blood , CD4-Positive T-Lymphocytes/immunology , Granuloma/immunology , Liver/immunology , Macrophages/immunology , Monocytes/immunology , Schistosomiasis mansoni/immunology , Animals , Antigens, Ly/metabolism , CD4-Positive T-Lymphocytes/metabolism , CD4-Positive T-Lymphocytes/parasitology , Cell Communication , Cell Transdifferentiation , Crosses, Genetic , Female , Granuloma/parasitology , Granuloma/pathology , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Immunologic Surveillance , Liver/metabolism , Liver/parasitology , Liver/pathology , Macrophage Activation , Macrophages/metabolism , Macrophages/parasitology , Male , Mice, Inbred C57BL , Mice, Transgenic , Monocytes/metabolism , Monocytes/parasitology , Ovum/growth & development , Ovum/immunology , Programmed Cell Death 1 Ligand 2 Protein/metabolism , Recombinant Proteins/metabolism , Schistosoma mansoni/growth & development , Schistosoma mansoni/immunology , Schistosomiasis mansoni/metabolism , Schistosomiasis mansoni/parasitology , Schistosomiasis mansoni/physiopathology , Up-Regulation
10.
Parasitol Int ; 63(1): 171-86, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24076429

ABSTRACT

Plasmodium falciparum malaria is responsible for the deaths of over half a million African children annually. Until a decade ago, dynamic analysis of the malaria parasite was limited to in vitro systems with the typical limitations associated with 2D monocultures or entirely artificial surfaces. Due to extremely low parasite densities, the liver was considered a black box in terms of Plasmodium sporozoite invasion, liver stage development, and merozoite release into the blood. Further, nothing was known about the behavior of blood stage parasites in organs such as the brain where clinical signs manifest and the ensuing immune response of the host that may ultimately result in a fatal outcome. The advent of fluorescent parasites, advances in imaging technology, and availability of an ever-increasing number of cellular and molecular probes have helped illuminate many steps along the pathogenetic cascade of this deadly tropical parasite.


Subject(s)
Brain/parasitology , Liver/parasitology , Lung/parasitology , Microscopy/methods , Plasmodium/cytology , Animals , Brain/immunology , Liver/immunology , Lung/immunology , Plasmodium/physiology
11.
PLoS One ; 8(8): e70842, 2013.
Article in English | MEDLINE | ID: mdl-23967119

ABSTRACT

Plasmodium falciparum malaria remains one of the most serious health problems globally and a protective malaria vaccine is desperately needed. Vaccination with attenuated parasites elicits multiple cellular effector mechanisms that lead to Plasmodium liver stage elimination. While granule-mediated cytotoxicity requires contact between CD8+ effector T cells and infected hepatocytes, cytokine secretion should allow parasite killing over longer distances. To better understand the mechanism of parasite elimination in vivo, we monitored the dynamics of CD8+ T cells in the livers of naïve, immunized and sporozoite-infected mice by intravital microscopy. We found that immunization of BALB/c mice with attenuated P. yoelii 17XNL sporozoites significantly increases the velocity of CD8+ T cells patrolling the hepatic microvasculature from 2.69±0.34 µm/min in naïve mice to 5.74±0.66 µm/min, 9.26±0.92 µm/min, and 7.11±0.73 µm/min in mice immunized with irradiated, early genetically attenuated (Pyuis4-deficient), and late genetically attenuated (Pyfabb/f-deficient) parasites, respectively. Sporozoite infection of immunized mice revealed a 97% and 63% reduction in liver stage density and volume, respectively, compared to naïve controls. To examine cellular mechanisms of immunity in situ, naïve mice were passively immunized with hepatic or splenic CD8+ T cells. Unexpectedly, adoptive transfer rendered the motile CD8+ T cells from immunized mice immotile in the liver of P. yoelii infected mice. Similarly, when mice were simultaneously inoculated with viable sporozoites and CD8+ T cells, velocities 18 h later were also significantly reduced to 0.68±0.10 µm/min, 1.53±0.22 µm/min, and 1.06±0.26 µm/min for CD8+ T cells from mice immunized with irradiated wild type sporozoites, Pyfabb/f-deficient parasites, and P. yoelii CS280-288 peptide, respectively. Because immobilized CD8+ T cells are unable to make contact with infected hepatocytes, soluble mediators could potentially play a key role in parasite elimination under these experimental conditions.


Subject(s)
CD8-Positive T-Lymphocytes/cytology , Immunization , Liver/immunology , Liver/parasitology , Malaria/immunology , Plasmodium yoelii/physiology , Adoptive Transfer , Animals , CD8-Positive T-Lymphocytes/immunology , Hepatocytes/immunology , Hepatocytes/parasitology , Malaria/prevention & control , Mice , Mice, Inbred BALB C , Sporozoites/physiology
12.
Biochemistry ; 48(47): 11152-4, 2009 Dec 01.
Article in English | MEDLINE | ID: mdl-19883122

ABSTRACT

Chloroquine (CQ) accumulation studies in live malaria parasites are typically conducted at low nanomolar CQ concentrations, and definition of CQ resistance (CQR) has been via growth inhibition assays versus low-dose CQ (i.e., via IC(50) ratios). These data have led to the nearly universally accepted idea that reduced parasite CQ accumulation is the underlying basis of CQR. Surprisingly, when quantifying CQR via cytocidal CQ activity and examining CQ accumulation at medically relevant LD(50) doses, we find reduced CQ accumulation is not the underlying cause of CQR.


Subject(s)
Antimalarials/metabolism , Antimalarials/toxicity , Chloroquine/metabolism , Chloroquine/toxicity , Drug Resistance/physiology , Plasmodium falciparum/drug effects , Vacuoles/drug effects , Dose-Response Relationship, Drug , Inhibitory Concentration 50 , Parasitic Sensitivity Tests , Plasmodium falciparum/growth & development , Plasmodium falciparum/metabolism , Plasmodium falciparum/ultrastructure , Vacuoles/metabolism , Vacuoles/ultrastructure
13.
Biochemistry ; 48(40): 9482-91, 2009 Oct 13.
Article in English | MEDLINE | ID: mdl-19725576

ABSTRACT

Mutations in the PfCRT protein cause chloroquine resistance (CQR), and earlier studies from our laboratory using plasma membrane inside-out vesicles (ISOV) prepared from yeast expressing recombinant PfCRT [Zhang, H., et al. (2004) Biochemistry 43, 8290-8296] suggested that the putative transporter mediates downhill facilitated diffusion of charged chloroquine (CQ). However, more recent experiments with a fluorescent CQ probe (NBD-CQ) presented in the accompanying paper (DOI 10.1021/bi901034r ) indicated that the CQR phenotype in live parasites is associated with a reduced rate of ATP-dependent CQ uptake into the digestive vacuole (DV). An altered rate constant for uptake has multiple interpretations. To further investigate this phenomenon, PfCRT proteins found in chloroquine-sensitive (CQS) and CQR strains of Plasmodium falciparum were purified from yeast engineered to express "yeast optimized" pfcrt genes, reconstituted into proteoliposomes (PL), and efflux of NBD-CQ was measured from these PL. A membrane-impermeant quencher was used to distinguish intra-PL NBD-CQ from extra-PL NBD-CQ vs time as well as resolve initial rates and rate constants for efflux. Efflux was investigated at a range of NBD-CQ concentrations, in the presence vs absence of pH gradients (DeltapH) and transmembrane potentials (DeltaPsi). Explicit turnover numbers for apparent PfCRT-mediated transport were then calculated under these conditions. Our data are consistent with a model wherein PfCRT catalyzes electrochemically downhill diffusion of NBD-CQ out of the DV, in response to DeltaPsi or DeltapH, at a rate that can partially compete with the ATP-dependent uptake of NBD-CQ by CQS parasites described in the previous paper. These data allow us to propose a refined model for altered CQ accumulation in CQR malarial parasites.


Subject(s)
4-Chloro-7-nitrobenzofurazan/analogs & derivatives , Chloroquine/analogs & derivatives , Chloroquine/metabolism , Fluorescent Dyes/metabolism , Membrane Transport Proteins/physiology , Plasmodium falciparum/physiology , Proteolipids/metabolism , Protozoan Proteins/physiology , 4-Chloro-7-nitrobenzofurazan/metabolism , Animals , Binding, Competitive , Biological Transport, Active/physiology , Catalysis , Drug Resistance , Humans , Membrane Potentials/physiology
14.
Biochemistry ; 48(40): 9471-81, 2009 Oct 13.
Article in English | MEDLINE | ID: mdl-19728740

ABSTRACT

Several models for how amino acid substitutions in the Plasmodium falciparum chloroquine resistance transporter (PfCRT) confer resistance to chloroquine (CQ) and other antimalarial drugs have been proposed. Distinguishing between these models requires detailed analysis of high-resolution CQ transport data that is unfortunately impossible to obtain with traditional radio-tracer methods. Thus, we have designed and synthesized fluorescent CQ analogues for drug transport studies. One probe places a NBD (6-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoic acid) group at the tertiary aliphatic N of CQ, via a flexible 6 C amide linker. This probe localizes to the malarial parasite digestive vacuole (DV) during initial perfusion under physiologic conditions and exhibits similar pharmacology relative to CQ, vs both CQ-sensitive (CQS) and CQ-resistant (CQR) parasites. Using live, synchronized intraerythrocytic parasites under continuous perfusion, we define NBD-CQ influx and efflux kinetics for CQS vs CQR parasites. Since this fluorescence approach provides data at much higher kinetic resolution relative to fast-filtration methods using (3)H-CQ, rate constants vs linear initial rates for CQ probe flux can be analyzed in detail. Importantly, we find that CQR parasites have a decreased rate constant for CQ influx into the DV and that this is due to mutation of PfCRT. Analysis of zero trans efflux for CQS and CQR parasites suggests that distinguishing between bound vs free pools of intra-DV drug probe is essential for proper kinetic analysis of efflux. The accompanying paper (DOI 10.1021/bi901035j ) further probes efflux kinetics for proteoliposomes containing purified, reconstituted PfCRT.


Subject(s)
Antimalarials/metabolism , Chloroquine/analogs & derivatives , Chloroquine/metabolism , Fluorescent Dyes/metabolism , Plasmodium falciparum/growth & development , Plasmodium falciparum/metabolism , 4-Chloro-7-nitrobenzofurazan/analogs & derivatives , 4-Chloro-7-nitrobenzofurazan/chemical synthesis , 4-Chloro-7-nitrobenzofurazan/metabolism , Animals , Antimalarials/pharmacology , Biological Transport, Active/drug effects , Chloroquine/pharmacology , Drug Resistance , Fluorescent Dyes/chemical synthesis , Humans , Kinetics , Malaria, Falciparum/metabolism , Malaria, Falciparum/parasitology , Malaria, Falciparum/prevention & control , Plasmodium falciparum/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...